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Clinical Trials Methods and Design
The Irbesartan in Heart Failure With Preserved Systolic
Function (I-PRESERVE) Trial: Rationale and Design
PETER CARSON, MD,1 BARRY M. MASSIE, MD,2 ROBERT MCKELVIE, MD, PhD,3 JOHN MCMURRAY, MD,4
MICHEL KOMAJDA, MD,5 MICHAEL ZILE, MD,6 AGATA PTASZYNSKA, MD,7 AND GERALD FRANGIN, MD,8
FOR THE I-PRESERVE INVESTIGATORS
Washington, DC; San Francisco, California, Hamilton, Ontario, Canada; Glasgow, Scotland; Paris, France;
Charleston, South Carolina; Princeton, New Jersey; Montpellier, France
ABSTRACT
Background: Although 40% to 50% of patients with chronic heart failure (HF) have relatively preserved
systolic function (PSF), few trials have been conducted in this population and treatment guidelines do not
include evidence-based recommendations.
Methods and Results: The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE)
is enrolling 4100 subjects with HF-PSF to evaluate whether 300 mg irbesartan is superior to placebo in
reducing mortality and prespecified categories of cardiovascular hospitalizations. The principal inclusion
criteria are age $60 years, heart failure symptoms, an ejection fraction $45%, and either hospitalization
for heart failure within 6 months or corroborative evidence of heart failure or the substrate for diastolic
heart failure. Additional secondary end points include cardiovascular mortality, cause-specific mortality
and morbidity, change in New York Heart Association functional class, quality of life, and N-terminal
pro-BNP measurements. Follow-up will continue until 1440 patients experience a primary end point. Sub-
studies will evaluate changes in echocardiographic measurements and serum collagen markers.
Conclusion: I-PRESERVE is the largest trial in this understudied area and will provide crucial informa-
tion on the characteristics and course of the syndrome, as well as the efficacy of the angiotensin receptor
blocker irbesartan.
Key Words: AT1-receptor blockers, ACE inhibition, Left ventricular function, Congestive heart failure.
Chronic heart failure (CHF) is a major and growing
cause of cardiovascular morbidity and mortality in patients
throughout the world.1 Previously, it had often been as-
sumed that most CHF patients have underlying systolic
dysfunction, which is responsible for their clinical presen-
tation. However, it has become increasingly apparent over
the last decade that many heart failure patients have a nor-
mal or nearly normal ejection fractionddescribed as heart
failure with preserved systolic function (HF-PSF).2,3 Data-
base reviews report a prevalence ranging from 40% to
71%.4 For example, the Framingham Heart Study reported
a 51% prevalence of HF-PSF (defined as a left ventricular
ejection fraction [LVEF] $50%)5 whereas the Cardiovas-
cular Health Study reported 55% of existing heart failure
subjects with HF-PSF (LVEF O50%).6 More recently, the
EuroHeart Failure Survey noted that among patients en-
rolled after hospitalization for heart failure, 49% of men
and 72% of women had an LVEF of 40% or more.7 In ad-
dition, the Acute Decompensated Heart Failure National
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Registry (ie, ADHERE) reported that in acute decompen-
sated HF patients with documented measurement of LVEF,
fully 51% of patients had preserved systolic function
(LVEF $0.40).8
Although these data consistently indicate that HF-PSF is
a problem of significant clinical magnitude, few clinical tri-
als have been conducted in this specific patient population
and there is no proven therapy. As a result, without
evidence-based recommendations, guideline groups such
as the European Society of Cardiology currently suggest
that HF-PSF be treated with b-blockers, verapamil-type cal-
cium antagonists, angiotensin-converting enzyme (ACE)
inhibitors, or diuretics, based only on specific patient co-
morbid conditions.9 In clinical practice, medical treatment
has been largely empiric.
The widespread role of the renin-angiotensin system
(RAS) in cardiovascular disease, particularly in systolic
heart failure, has led to investigation of RAS inhibitors in
HF-PSF. Specifically the angiotensin receptor blockers
(ARBs) have been of interest because of their ability to
more completely antagonize the effects of angiotensin II
and their excellent tolerability. The only prospective out-
come trial in HF-PSF, the recently completed CHARM-
PRESERVED study,10 reported results that suggested
a promising role for ARBs in HF-PSF, although these re-
sults cannot be seen as conclusive.
The Irbesartan in Heart Failure with Preserved Systolic
Function (I-PRESERVE) trial, the largest trial in this under-
studied area, was designed to definitively test the hypo-
thesis that an ARB, irbesartan, would improve clinical
outcomes in patients with HF-PSF. The purpose of this ar-
ticle is to describe the protocol and processes that will be
used to collect data and to test the hypothesis of the trial.
Design of the I-PRESERVE Trial
Objectives
The objectives of I-PRESERVE trial are to study the ef-
fects of irbesartan on morbidity and mortality outcomes,
symptom scores, and quality of life in a patient population
with heart failure and preserved systolic function.
Study Population
Specific inclusion criteria are listed in Table 1. These in-
clusion criteria were designed to enroll a patient population
similar to that observed in epidemiologic and community-
based studies, with ongoing heart failure symptoms and
an increased likelihood of clinical events. Thus the require-
ment for age $60 years, LVEF $45%, and recent hospital-
ization for heart failure or moderate to severe symptoms
and corroborative objective evidence of heart failure or
a cardiac substrate for diastolic dysfunction were required
for the study.
The exclusion criteria are shown in Table 2. These were
designed to exclude patients with confounding medical
conditions or an inability to meaningfully participate in
the trial.
Study Design
I-PRESERVE is a placebo-controlled, double-blind,
multicenter, international, parallel-group study. Figure 1
summarizes the study design. Subjects are randomized ac-
cording to a 1:1 ratio of irbesartan to placebo, stratified
by site and by use of ACE inhibitors at baseline, using an
automated, central randomization system. ACE inhibitor
use is limited to those patients with a specific indication
other than hypertension (such as diabetes mellitus with
complications and significant coronary or peripheral artery
disease), In addition, only one third of patients at each site
are permitted to be randomized with ACE inhibitor con-
comitant therapy.
This study will be conducted according to the ethical
principles described in the Declaration of Helsinki and
will have received Institutional Review Board/Independent
Ethics Committee approval before initiation. Freely given
written informed consent must be obtained from every sub-
ject before trial participation.
Study Endpoints
The primary end point is defined as time from randomi-
zation to the first occurrence of the composite outcome of
Table 1. Key Inclusion Criteria for Patients in the
I-PRESERVE Study
Male or female of age $60 years
Left ventricular ejection fraction (LVEF) $45%
Willing to provide written informed consent
Current heart failure symptoms consistent with New York Heart
Association (NYHA) Class II or higher as specified as follows:
Hospitalization for heart failure
within the last 6 months and
currently symptoms of
NYHA II-IV
or Currently symptoms of NYHA
III-IV and corroborative
evidence (at least 1 of the
following):
A Chest x-ray evidence of
pulmonary congestion
A ECG evidence of moderate
or severe LVH (at least 1 of
the following):
SV1 1 RV5 or RV6O3.5 mV
(35 mm at normal standard)
RaVL O1.1 mV (11 mm at
normal standard)
RaVL 1 SV3 O2.8 mV in
men or 2.0 mV in women
(28 mm and 20 mm at
normal standard,
respectively)
A LBBB on ECG
A Echocardiographic evidence
of any 1 of the following:
LVH (PW 1 IVS thickness)/
2 $1.3 cm or posterior wall
thickness $1.2 cm
Enlarged left atrium (LA) in
the absence of atrial
fibrillation:
women $42 mm
men $46 mm
ECG, electrocardiogram; LBBB, left bundle-branch block; LVH, left
ventricular hypertrophy.
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death (all cause) or cardiovascular hospitalization. Cardio-
vascular hospitalizations are defined as:
Protocol specified cardiovascular hospitalizations for
a primary cause of: worsening heart failure, unstable an-
gina, myocardial infarction, ventricular dysrhythmia,
atrial dysrhythmia, or stroke.
The endpoint additionally includes myocardial infarction
or stroke occurring during any hospitalization at any point
during the study.
Secondary endpoints include the effect of irbesartan as
compared with placebo in reducing the risk of: cardiovascu-
lar death; all-cause mortality; combined vascular endpoint:
cardiovascular death, nonfatal myocardial infarction (MI)
or nonfatal stroke; or combined HF endpoint: HF mortality
or hospitalizations; the effect of irbesartan as compared with
placebo on: quality of life as measured by the Minnesota
Living with Heart Failure questionnaire, change in New
York Heart Association (NYHA) functional class, change
in patient global assessment of symptoms, N-terminal
B-type natriuretic peptide levels in blood.
Sample Size and Statistical Plan
The trial was designed to provide 90% power to detect
a 14.5% reduction in the primary event rate with a 2-sided
type I error rate of 0.05, which would require a total of
1440 patients to experience a first, primary event. The sam-
ple size was estimated based on data from the placebo group
in the Digitalis Investigation Group ancillary trial in which
998 patients with LVEFO45% were followed for a mean of
36 months. Using similar endpoints, an annual primary
event rate (death of any cause or cardiovascular hospital-
izations) of 18% was estimated for the placebo group.
With this projected event rate, a sample size of at least
3600 subjects with 2 years of uniform recruitment and
a minimum follow-up of 2 years was anticipated to attain
1440 primary events. By the second year of the study, it
became apparent that the total event rate was lower than
projected. As a result, in April 2004, the I-PRESERVE
Executive Committee recommended an increase in the
sample size to 4100 patients to reach the requisite 1440
events within the initial projected timeline.
The primary end point and secondary end points based
on clinical outcomes will be analyzed based on the time
to the first occurrence. Survival curves by treatment will
be estimated using the Kaplan-Meier procedure and com-
pared using a 2-sided log-rank test. The treatment effect
will be modeled using Cox proportional hazards models
and adjusted relative risks will be estimated from them.
Substudies
Two formal substudies are being conducted by selected
I-PRESERVE sites:
Table 2. Key Exclusion Criteria for Patients in the
I-PRESERVE Study
Evidence of primary hypertrophic or restrictive cardiomyopathy or
systemic illness known to be associated with infiltrative heart disease
Cor pulmonale or other causes of right heart failure not related to left
ventricular dysfunction
Pericardial constriction
Life-threatening or uncontrolled dysrhythmia including atrial fibrillation
with a resting ventricular rate O120 beats per minute
Subjects with an implantable cardioverter-defibrillator that has discharged
in the past 3 months
Stroke or cerebrovascular surgery within 3 months
Clinically significant pulmonary disease, as evidenced by prior mechanical
assisted ventilation, hospitalizations, or use of oral corticosteroids for
pulmonary decompensation within 12 months, requirement of home
oxygen or significant pulmonary fibrosis
Sitting systolic BP !100 mm Hg
Sitting systolic BP O160 mm Hg or diastolic BP O95 mm Hg despite
therapy with antihypertensive medications other than the study drug
Known systemic diseases that may limit life expectancy to!3 years or are
likely to result in hospitalization within the next 6 months
Significant laboratory abnormalities, such as hemoglobin !11 mg/dL,
creatinine O2.5 mg/dL, AST or ALT O33 upper limit of normal
Clinical evidence of uncontrolled hyperthyroidism or hypothyroidism
Known or suspected bilateral renal artery stenosis
Any patient characteristic that may interfere with compliance
Participation in any study of an investigational drug
ENROLLMENT
Period A
Single-blind
2 weeks
R
75 mg* 150 mg 300 mg
W2 W4 W8 M6 M10
M10
TITRATION
Period B
MAINTENANCE
Period C
IRBESARTAN
M24-48
Final Visit
PLACEBO
Fig. 1. I-PRESERVE trial design. r 5 1:1 central randomization; * 5 Forced titration
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1. Echocardiographydfew data exist on left ventricular
size and function in HF-HSF. This substudy will use
sequential echo Doppler imaging at baseline and
month 10 to assess a number of parameters associated
with diastolic function. The primary hypothesis is that
treatment with irbesartan results in improvement in
left atrial area. Secondary objectives are measurement
change in Epk/Ea and in LV mass index, description of
baseline LV size and function, and assessment of the
relationship between LA size and the primary clinical
outcome. The design will enroll 624 subjects to yield
500 evaluable echo studies.
2. Collagen markersdcollagen markers have been noted
to be elevated in heart failure, although no data exist in
HF-PSF. This study will measure peripheral collagen
markers, pro-collagen Type III and osteopontin, at
baseline and 6 months. The primary objective will be
to compare change in pro-collagen Type III between ir-
besartan and placebo. Secondary objectives will mea-
sure differences in treatment groups with collagen
markers and the relation of baseline values to the pri-
mary clinical outcome. The study is designed for en-
rollment of 312 subjects to yield at least 200 samples.
Organization
The I-PRESERVE Executive Committee includes 2 co-
principal investigators and 4 other membersdall of whom
are cardiologists. The committee receives operational assis-
tance from representatives of the sponsoring companies,
Bristol-Myers Squibb and Sanofi-Aventis, who are ex-
officio members. The Executive Committee was responsible
for the development of the study protocol and amendments
and overseeing the conduct of the trial. The Executive Com-
mittee also functions as the Publication Committee for this
trial. A Steering Committee, consisting of the Executive
Committee plus the national coordinators from the partici-
pating countries, provides additional scientific input to the
Executive Committee and guidance on the logistics of the
study. An End-Point Adjudication Committee reviews all
clinical events during the trial and adjudicates all study end-
points. The Endpoint Committee chair is a member of the
Executive Committee.
The Data Safety Monitoring Board is independent of the
study committees and operational teams. At least 2 interim
evaluations of all-cause mortality are planned and will use
predefined stopping rules for major safety concerns.
Discussion
Despite the growing importance of HF-PSF, this remains
an understudied area. The paucity of clinical trials in HF-
PSF reflects a number of factors, including the relatively re-
cent recognition of the existence and importance of this
condition, disagreement concerning its pathophysiology
as well as lack of a simple and straightforward diagnostic
test. However, our understanding of the syndrome is
increasing, and there is growing evidence that most patients
with this presentation have underlying left ventricular dia-
stolic dysfunction. Recent mechanistic studies in patients
with heart failure and LVEF O50%, in whom other etiolo-
gies such as valvular, pericardial disease, and high output
states have been excluded, indicate that there are demon-
strable abnormalities of diastolic functiondparticularly
impaired relaxation or reduced left ventricular compli-
ance.11,12 Echocardiographic abnormalities, such as abnor-
malities of mitral valve flow and annular velocities,
pulmonary venous flow, pulmonary artery pressures, and
left atrial size are usually present, although they are not spe-
cific for diastolic dysfunction. Elevated natriuretic peptide
levels are also often present, although these are also not
specific for this diagnosis.
Epidemiologic and cohort studies provide consistent in-
formation about the characteristics of patients of patients
with HF-PSF.3–6 These patients are generally older than
those with systolic dysfunction and much more likely to
be women. The majority have a history of hypertension,
which often persists after the development of heart failure.
Although many may have underlying coronary disease, pre-
vious myocardial infarction is far less common than in pa-
tients with systolic dysfunction. These characteristics are
consistent with the importance of left ventricular hypertro-
phy and ‘‘aging myocardium’’ (presbycardia) as mecha-
nisms of diastolic dysfunction. Although mechanistic
studies, as discussed previously, demonstrate that abnor-
malities of diastolic function are invariably present in HF-
PSF patients, reviews of larger less-controlled databases
have noted that indices of diastolic function are also fre-
quently abnormal in elderly patients who are without symp-
toms and also note the high rate of comorbidites.4 There is,
then, disagreement concerning the relative contribution of
diastolic dysfunction to heart failure in a population prone
to other comorbidities. Therefore, unlike in systolic heart
failure, in which the concepts linking systolic dysfunction
and remodeling to the development and progression of
the syndrome are increasingly understood and accepted,
there is still controversy about the development and pro-
gression of HF-PSF. However, as in systolic heart failure,
preclinical and clinical evidence suggest that the RAS is a
contributing factor in the development of HF-PSFd
principally through the trophic effects of angiotensin II in
the vasculature and myocardium, but perhaps also through
myocardial fibrosis mediated by aldosterone.13,14 Although
several animal models of diastolic dysfunction have been
available, only recently has an animal model of HF-PSF
become available: Dahl salt-sensitive rats fed a high salt
diet beginning at 7 weeks developed high blood pressure,
compensated left ventricular hypertrophy (LVH), and later
transitioned into HF-PSF. Unlike previous models, these an-
imals developed heart failure in the absence of systolic dys-
function. In these rats, treatment with an ARB blocked the
progression to LVH and transition into HF-PSF.15
Clinical trials investigating the effects of RAS inhibition,
using either ACE inhibitors or ARBs, in HF-PSF are still
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limited but increasing. Several small studies provided the
first evidence that these agents may be effective in this set-
ting. A retrospective analysis of Vasodilator Heart Failure
Trial (ie, V-HeFT) I and II for LVEFO35% patients (mean
LVEF 46%) suggested benefit for the ACE inhibitor enalap-
ril.16 In a placebo-controlled crossover study, the ARB losar-
tan was shown to increase exercise tolerance and improve
quality of life in subjects with diastolic dysfunction and a hy-
pertensive response to exercise.17 Finally, in an outcomes tri-
al, CHARM-PRESERVED, the ARB candesartan reduced
hospitalizations for HF, but did not significantly reduce the
primary composite endpoint of cardiovascular death or HF
hospitalization.10 Thus, although there is a strong mechanis-
tic rationale for further investigation of RAS inhibitors in this
clinical syndrome, there remains a lack of clinical data upon
which to base guidelines for the use of these agents in treat-
ment of HF-PSF.
The ARB irbesartan was felt to be particularly appropri-
ate for this trial because, besides being a potent and
well-tolerated antihypertensive agent, it has proven to be
effective in reversing LVH in the Swedish Irbesartan Left
Ventricular Hypertrophy Investigation versus Atenolol
(ie, SILVHIA) trial18 and it also reduced the occurrence of
CHF compared with both placebo and amlodipine in Irbe-
sartan Diabetic Nephropathy Trial (ie, IDNT).19
I-PRESERVE was designed to test a RAS inhibitor in
a patient population that closely matched the HF-PSF pop-
ulations described in databases. Because older patients pre-
dominate in these databases, I-PRESERVE targeted an older
population by excluding patients younger than age 60. The
LVEF lower limit criterion was also crucial for a protocol in
this area. As noted previously, at the time of design of
I-PRESERVE, few clinical trial data existed for heart failure
with an ejection fraction higher than 40%. However, avail-
able evidencedsuch as in the Duke database20 (HF-PSF pa-
tients selected to undergo cardiac catheterization) with
a mean LVEF of 54%dsuggested that the usual LVEF in
this syndrome was considerably higher than this level. To
best typify the population, and to study patients without sys-
tolic heart failure, a minimum ejection fraction of 45% was
chosen. The protocol also excluded patients with previous
systolic dysfunction, such as those that had an increased
ejection fraction during b-blocker therapy or following re-
vascularization, because these patients are likely to be path-
ophysiologically distinct from other HF-PSF patients.
Unlike systolic dysfunction, with a lower LVEF, HF-PSF
does not have an easily ascertained diagnostic marker. Non-
invasive measurements of diastolic function have been con-
troversial, but, moreover, are not easily obtained in a large
international clinical trial. Although only partially available
during the design of I-PRESERVE, the data by Zile and
colleagues, discussed previously, confirm that selected pa-
tients with HF-PSF invariably have echocardiographic
and hemodynamic abnormalities of diastolic dysfunc-
tion.11,12 These important findings indicate that it is not
necessary to routinely measure invasive indices of diastolic
function in patients with clinical symptoms and signs of
HF-PSF to establish that diastolic heart failure is present.
To strengthen the diagnosis of heart failure, I-PRESERVE
does require additional clinical criteria for entry which
can take 1 of 2 pathways: continuing NYHA II-IV symp-
toms at enrollment and a heart failure hospitalization within
6 months or continuing NYHA III-IV symptoms, with ob-
jective indication of decompensation (chest x-ray), or evi-
dence suggesting a structural basis of diastolic dysfunction
(echocardiographic or electrocardiographic evidence).
The former pathway, with less advanced symptoms, adds
the hospitalization criterion to improve diagnostic accura-
cy but also to enhance the event rate, because previous da-
ta suggest that patients hospitalized for heart failure will
likely be hospitalized again within 6 months.21 The latter
pathway requires a higher level of symptoms and also adds
structural features suggesting diastolic dysfunction. It is
worth noting that the CHARM-PRESERVED protocol
did not require either a HF hospitalization or structural
criteria for entry.22
The primary composite endpoint for I-PRESERVE is all-
cause mortality or protocol-specified cardiovascular hospi-
talization, analyzed as time to first event. This inclusive end-
point was selected because it optimally reflects the
outcomes of this patient population. Although heart failure
may be the cause of initial presentation, available data sug-
gest that the minority of cardiovascular events that occur in
this population are primarily attributable to heart failure. At
the time of trial design, the available clinical trial data, the
Digitalis Investigation Group study reported that 60% of
hospitalizations had a primary cardiovascular cause, whereas
only 20% were primarily from heart failure.23 More recently
the CHARM Preserved investigators have reported similar
data.10 The I-PRESERVE protocol stipulates specific car-
diovascular categories of hospitalization that represented
potentially realistic targets for therapy: heart failure, unsta-
ble angina, myocardial infarction, atrial arrhythmias, and
ventricular arrhythmias. Documented myocardial infarction
and stroke occurring at any time during the trial are also in-
cluded as primary end points as they represent irreversible
events. The protocol also stipulates that a primary end point
hospitalization would require an overnight duration and ei-
ther parenteral or augmented oral therapy for the prespeci-
fied cardiovascular condition.
Because there is no proven therapy for HF-PSF, there is
also no obvious mandated therapy. However, patients with
HF-PSF are likely to have other comorbidities and require
treatment for conditions such as hypertension, coronary ar-
tery disease, and atrial fibrillation. Accordingly, because
background treatment for these conditions would need to
be allowed, only ARB treatment would be an absolute ex-
clusion. However, because there is significant pharmaco-
logic overlap with ARBs, ACE inhibitor therapy was
restricted to patients who had a specific indication for
these agents, such as diabetic nephropathy or advanced
atherosclerotic disease including confirmed myocardial or
cerebrovascular infarctions. Entry of patients requiring on-
going use of an ACE inhibitor was limited to one third of
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the population, because I-PRESERVE was not intended to
be a trial of combination ARB and ACE-inhibitor
therapy. This level of ACE inhibitor usage was also con-
sistent with that observed in community practice at the
time I-PRESERVE was designed.
An important feature of I-PRESERVE concerns natri-
uretic peptides. Brain natriuretic peptides (BNP) have
been noted to be elevated in diastolic heart failure, but obser-
vations are limited. Largely for this reason, BNP measure-
ment in any form is not an entry criteria in this study:
however, pro-BNP will be measured in all patients at base-
line and at 2 points of follow-up. This will be the largest da-
taset of natriuretic peptides in HF-PSF, and I-PRESERVE
will provide strong evidence for the range of values for
pro-BNP occurring in this syndrome. Because recent
data with BNP in systolic heart failure supports a strong
prognostic role,24 the relation pro-BNP to clinical events
in I-PRESERVE will of great interest. Finally, the trial de-
sign will assess the effect of irbesartan treatment on pro-
BNP levels.
Conclusion
HF-PSF represents a large part of the overall morbidity
and mortality burden of chronic heart failure. It is the pre-
dominant form of heart failure in the elderly and in
women. The I-PRESERVE protocol, the largest HF-PSF
study to date, is designed to examine the prognosis and re-
sponse to irbesartan in an understudied and poorly under-
stood area.
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versitair Ziekenhuis Leuven Gasthuisberg).
Brazil
E. Mesquita (National Coordinator); PIs: D. Albuquer-
que (Hops Univ Pedro Ernesto - UERJ), A. DePaola (Univ
Federal de Sao Paolo), G. Feitosa (Hospital Santa Isabel),
J.F. Kerr Saraiva (Hosp Celso Piero Da Puccamp), E. Mes-
quita (Hospital Pro-Cardiaco), M. Moreira (Hospital Felicio
Rocho), S. Rassi (Hosp Das Clinicas Da UFG), S. Salles
Xavier (Hos Uni Clementino Fraga Filho).
Canada
J. Rouleau (National Coordinator); PIs: C. Constance
(Hopital Masonneuve-Rosemont), E. Davies (Scarborough
General Hospital), C. Fortin (Neufort, Inc.), P. Harvey (Uni-
versity Health Network), D. Isaac (Univeristy of Calgary),
P. Klinke (Victoria Heart Institute Foundation), K. Kwok
(Etobicoke Cardiology Assoc.), R. Leader (Baywood
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Medical Center), P. Ma (Heart Health Institute), R. McKel-
vie (Hamilton General Hospital), G. Moe (St. Michael’s
Hospital), A. Mukherjee (Digital Cardiology), J. Parker
(Mount Sinai Hospital), G. Proulx (Hospial Laval), D. Sa-
vard (Medi Recherche), F. St-Maurice (Viacar Recherche
Clinique), L. Yao (Humber River Regional Hospital).
Czech Rep.
J. Hradec (National Coordinator); PIs: J. Drazka (Ma-
sarykova Nemocnice), P. Fridl (Institut Klinicke A Exper-
mentalni Mediciny), J. Hradec (General University
Hospital), H. Skalicka (Poliklinika Praha 9).
Denmark
L. Kober (National Coordinator); PIs: J. Bronnumschou
(H:S Amager Hospital), C. Torp-Pedersen (Bispebjerg
Hospital).
France
Yves Juilliere (National Coordinator); PIs: G. Amat
(Centre Hospitalier De Vichy), F. Bauer (Centre Hospitalier
Universitaire Hopital Charles), J. Bouvier (Centre Hospital-
ier De Cholet), B. Charbonnier (C.H. Regional et Universi-
taire Hopital Trousseau), J. Demarcq (Hopital Victor
Provo), R. Fouche (Centre Hospitalier Andre Boulloche),
F. Funck (Centre Hospitalier Rene Dubos),
M. Genest (Centre Hospitalier Leon Binet), Yves Juil-
liere (Hospital Brabois Adultes), J. Kahn (C.H. Intercom-
munal De Poissy - Saint Germain en Laye), R. Ketelers
(Clinique Du Bois), M. Komajda (Groupe Hospitalier
Pitie-Salpetriere), M. Martelet (Centre Hospitalier De Lan-
gres), T. Olive (Centre Hospitalier De Gap), J. Poulard
(Centre Hospitalier D’Abbeville), M. Richard (Centre Hos-
pitalier General Hopital Broussais), J.L. Roynard (Centre
Hospitalier De Dax).
Germany
R. Dietz (National Coordinator); PIs: C. Angermann
(Klinikum Der Universitaet Wuerzburg), M. Boehm (Uni-
versita¨tskliniken Des Saarlandes), H. Figulla (Klinikum
Der Friedrich-Schiller-Universita¨t Jena), F. Freytag (Krei-
skrankenhaus Gunzenhausen), L. Goedel-Meinen
(Deutsches Herzzentrum), J. Hein (Praxis Dr. Jasper Hein),
C. Hengstenberg (Klinikum Der Universitaet Regensburg),
T. Horacek (Evangelisches Krankenhaus), J. Monti (Franz-
Volhard-Klinik Berlin), T, Muenzel (Klinikum Der Jo-
hannes-Gutenberg-Universitaet), B. Pieske (Klinikum Der
Georg-August Universitaet), H. Olbrich (Asklepios Kliniken
Langen-Seligenstadt), M. Rachor (Sta¨dtisches Kranken-
haus Bad Homburg), H. Schultheiss (Universita¨tsklinikum
Benjamin-Franklin), U. Sechtem (Robert-Bosch-Kranken-
haus Stuttgart), H. Stahl (Stahl, Hans-Detlev), K. Stangl
(Universitaetsklinikum Charite), H. Stempfle (Medizini-
sche Klinik Innenstadt), R. Willenbrock (Krankenhaus
St. Elisabeth Und St. Barbara), J. Wunderlich (Kardiologi-
sche Gemeinschaftspraxis).
Greece
D. Cokkinos (National Coordinator); PIs: D. Alexopou-
los (University Hospital Of Patras), F. Kardaras (Evagelis-
mos Hospital), D. Kremastinos (Onassis Cardiac Surgery
Centre), I. Nanas (Alexandra University Hospital).
Hungary
I. Edes (National Coordinator); PIs: T. Buza (Budagyon-
gye Hospital), I. Edes (Debrecen University), T. Forster
(Szeged University), K. Simon (Siofok Varosi Korhaz).
Ireland
K. McDonald (National Coordinator); PI: V. Maher
(Adelaide And Meath Hospital), K. McDonald (St. Vin-
cent’s Hospital).
Italy
L. Tavazzi (National Coordinator); PIs: E. Bernobich
(Ospedale Cattinara - Univ.Trieste), D. Cucinotta (Azienda
Ospedaliera Policlinico S.Orsola M.Malpighi), E. Feraco
(I.N.R.C.A. Divisione Cardiologia), P. Fioretti (Ospedale
Santa Maria Della Misericordia), L. Moretti (Ospedale
Mazzoni), R. Nami (Policlinico Le Scotte-Ist.Clin.
Med.Iii-U.O. Ipertensione), C. Prati (Azienda Unita’ Sani-
taria Locale Piacenza), R. Rozzini (U.O. Geriatria - Osp.-
Nuova Poliambulanza), U. Senin (Policlinico S.Maria
Della Misericordia - U.O. Geriatria), L. Tavazzi (Ircss Po-
liclinico S. Matteo -Divisione Di Cardiologia), M. Volpe
(Az.Osp.S’Andrea / Dip.To Med.Sperimentale).
Mexico
C. Diaz (National Coordinator); PIs: C. Calvo (Hospital
Civil Juan I. Menchaca), A. Cruz (Hospital Norte De Pe-
mex), E. Gomez (Centro Medico Nacional 20 De Noviem-
bre Issste), I. Hernandez (Hospital Juarez De Mexico), E.
Meaney (Hospital Regional 1ero De Octubre Issste), A.
Orea (Instituto Nacional De Ciencias Medicas Y Nutricion
S.Z.), M. Rosas (Instituto Nacional De Cardiologia), C.
Sanchez (Hospital De Enf. Cardiovasculares Y Del Torax
#34 Imss), E. Villegas (Central Medico Quirurgica De
Aguascalientes).
The Netherlands
J. Cornel (National Coordinator); PIs: P. Bronzwaer (De
Heel Zaans Medisch Centrum), J. Cornel (Medisch Centrum
Alkmaar), L. Cozijnsen (Gelre Ziekenhuizen, Locatie Juli-
ana), M. De Leeuw (Wilhelmina Ziekenhuis), A. Derks
(Streekziekenhuis Midden-Twente), D. De Waard (Antonius
Ziekenhuis), P. Dunselman (Amphia Ziekenhuis, Lokatie
Molengracht), M. Freericks (Ikazia Ziekenhuis), B. Hamer
(Meander Medisch Centrum, Lokatie Lichtenberg), D.
Hertzberger (Canisius Wilhelmina Ziekenhuis), M. Nagels-
mit (Scheper Ziekenhuis), P. Nierop (Sint Franciscus Gas-
thuis), J. Posma (Martini Ziekenhuis Lokatie Van Swieten),
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L. Slegers (Sint Joseph Ziekenhuis), F. Van Asperdt (Elker-
liek Ziekenhuis, Lokatie Helmond), M. Van Daele (Maas-
landziekenhuis), M.Van Der Linden (Vlietland Ziekenhuis
Vlaardingen), P. Van Rossum (Rivas Medizorg), D. Van
Veldhuisen (UMCG, Universitair Medisch Centrum Gronin-
gen), J. Verheul (Flevoziekenhuis), J.Wesdorp (Spaarne Zie-
kenhuis), A. Withagen (Reinier De Graaf Groep Delft).
Norway
J. Otterstad (National Coordinator); PIs: E. Aaser (Bae-
rum Hospital), J. Otterstad (Vestfold Central Hospital), C.
Von Brandis (Sentralsjukehuset I Rogaland).
Poland
P. Ponikowski (National Coordinator); PIs: M. Dluzniew-
ski (Wojewodzki Szpital Brodnowski), Z. Gaciong (Klinika
Nadcisnienia Tetniczego Akademii Medycznej), Z. Kubica
(Akademia Medyczna Im. L. Rydygiera), M. Ogorek (Sa-
modzielny Szpital Wojewodzki), P. Ponikowski (Szpital
Wojskowy), W. Ruzyllo (Instytut Kardiologii), M. Tendera
(Slaska Akademia Medyczna), M. Ujda (Powiatowy Szpital
Specjalistyczny), B. Zalska (Zoz Mswia).
Portugal
R. Gomes (National Coordinator); PIs: D. Brito (Hospital
De Santa Maria), M. Cortez (Hospital Pedro Hispano), C.
Fonseca (Hospital Sao Francisco Xavier).
Russia
V. Mareev (National Coordinator); PIs: O. Alexandrov
(Russian State Medical University), V. Ardashev (Central
Military Clinical Hospital Burdenko), B. Bart (Russian
State Medical University), S.I. Bogoslovskaya (Saratov
Scientific Research Institute Of Cardiology), I. Bokarev
(Municipal Clinical Hospital # 20), S. Fitilev (City Cardiol-
ogy Prophylactic Center), I. Fomina (Municipal Clinical
Hospital #61), M. Glezer (Municipal Clinical Hospital #
59), B. Goloschekin (St. Petersburg City Hospital # 15),
E. Grineva (St. Petersburg State Medical University), A.
Ivleva (Outpatient Clinic #1), V. Kostenko (St. Petersburg
Emergency Research Institute), V. Mareev (Moscow Cardi-
ology Research Center), V. Milyagin (Smolensk State Med-
ical Academy Of Ministry Of Public Health), S. Minkin
(Consultative And Diagnostic Center # 1), N. Nosova
(St. Petersburg Outpatient Clinic # 34), L.I. Olbinskaya
(Moscow Medical Academy), V. Orlov (Medical Academy
Of Postgraduate Ed.), N. Perepetch (Mechnikov Medical
Academy), M. Repin (St. Petersburg City Outpatient Clin-
ic # 40), M. Ruda (Moscow Cardiology Research Center),
A. Sherenkov (Krasnogvardeysky District Medical-
Physiology), E. Shlyakhto (St. Petersburg Cardiology Re-
search Institute), B. Sidorenko (Govermental Central Clin-
ical Hospital), A. Sinopalnikov (Institute Of Postgraduate
Medical Education Of Dm), A. Starodubtsev (Municipal
Clinical Hospital # 23 Named After Medsantrud), G. Stor-
ozhakov (Russian State Medical University), Y. Vasyuk
(Moscow Medical Stomatological Institute), A. Vishnevsky
(St. Petersburg City Pokrovskaya Hospital), G. Zalevsky
(St. Petersburg Municipal Clinical Hospital # 28), D.
Zateystchikov (Municipal Clinical Hospital # 51).
South Africa
A. Dalby (National Coordinator); PIs: A. Dalby (Milpark
Hospital), C. Libhaber (Chris Hani Baragwanath Hospital),
D. Naidoo (Nelson R. Mandela School Of Med), J. Patel
(St. Augustine’s Medical Centre 2), L. Steingo (Morning-
side Clinic).
Spain
J. Gonzalez-Juanatey (National Coordinator); PIs: M.
Anguita Sanchez (Hospital Universitario Reina Sofia), C.
Calvo Gomez (Hospital Clinico Univ. De Santiago De
C.), J. Casademont (Hospital Clinic), P. Conthe (Hospital
Gral. Univ. Gregorio Maranon), E. De Teresa Galvan (Hos-
pital Univ. Virgen De La Victoria), J. M. Fernandez (Hos-
pital Universitario Virgen Macarena), I. Ferreira (Hospital
Clinico Univ. Lozano Blesa), J. Forteza (Hospital Son Du-
reta), J. Garcia Puig (Hospital Universitario La Paz), J.
Gonzalez-Juanatey (Hospital Clinico Univ. De Santiago
De C.), L. Pastor (Hospital Universitario De Valme), F. Ri-
docci-Soriano (Hospital General Univ. De Valencia), F. So-
ria (Hospital Univ. Virgen De La Arrixaca), C. Suarez
(Hospital Universitario De La Princesa), J. Zamorano (Hos-
pital Clinico San Carlos).
Sweden
U. Dahlstrom (National Coordinator); PIs: G. Ahlmark
(Falun Hospital), K. Boman (Skelleftea County Hospital),
U. Dahlstrom (Linkoping University Hospital), C. Hoglund
(City Heart Stockholm Kb), T. Kahan (Danderyd Hospital),
M. Lycksell (Sundsvall County Hospital),M. Schaufelberger
(Sahlgrenska University Hospital/Ostra), R. Willenheimer
(University Hospital Mas).
Switzerland
F. Follath (National Coordinator); PI: A. Gallino (Gallino
Augusto), W. Estlinbaum (Kantonsspital).
U.K.
T. McDonagh (National Coordinator); PIs: J. Cleland
(Hull Royal Infirmary), J. McMurray (Western Infirmary),
J. Purvis (Altnagelvin Area Hospital), M. Pye (York District
Hospital), J. Stephens (Oldchurch Hospital).
USA
National Coordinators: D. Kitzman, C. O’Connor.
Alabama
A. Bouchard (Cardiology P.C.).
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Arizona
M. Goldberg (Saguaro Clinical Research), S. Goldman
(Southern Arizona VA Health Care System), B. Peart
(Southwest Heart), G. Wong (Cardiac Solutions).
Arkansas
Y. Aude (Cent. Arkansas Vet Health Sys.).
California
R. Davidson (Capri), B. Greenberg (UCSD Medical Cen-
ter), B. Massie (San Francisco Veterans Affairs Medical
Center).
Connecticut
W. D. Hagar (UConn Health Center).
Florida
K. Adams (Jacksonville Heart Center), L. Hendley
(Benchmark Clin Mangt Group), T. Hilton (Jacksonville
Heart Center), M. Lakow (Florida CV Research, L.C.), R.
Schneider (The Broward Heart Group, PA), D. Schocken
(University Of South Florida-College Of Medicine).
Illinois
B. Clemson (Heartcare Midwest).
Indiana
J. Ortiz (Research Institute Of Middle America).
Kentucky
M. Bessen (MCC Research Foundation).
Louisiana
J. Ghali (Louisiana State University Health Sciences
Center-Shreveport), B. Iteld (Louisiana Heart Center).
Maine
R. Weiss (Androscoggin Cardio. Assoc.).
Maryland
R. DiBianco (Cardiovascular Consultants), S. Mason
(Midatlantic Cardiovascular Associates), J. Porterfield
(Midatlantic Cardiovascular Associates, PA).
Massachusetts
S. Bilazerian (Pentucket Medical Associates), M. Semi-
gran (Massachusetts General Hospital), V. Desai (Charles
River Medical Associates).
Michigan
H. Colfer (Northern Michigan Hospital), M. Guglin
(John D Dingell VAMC).
Minnesota
I. Anand (Univ. of Minnesota Medical School).
Missouri
M. Rich (Washington University School Of Medicine).
Nebraska
D. Chapman (Heart Consultants, PC), A. Reyes
(Creighton Cardiac Center).
Nevada
W. Graettinger (Reno VAMC).
New Jersey
M. Gelernt (Cardiovascular Associates Of The Delaware
Valley).
New Hampshire
B. Hettleman (Dartmouth-Hitchcock Medical Center).
New Mexico
R. Orchard (New Mexico Heart Institute).
New York
L. Baruch (VA Medical Center), R. Benton (Capital Car-
diology Associates, PC), C. Liang (University Of Rochester
Medical Center), R. Silverman (Silverman Heart Care
Center).
North Carolina
P. Campbell (North East Medical Center), D. Kitzman
(Wake Forest University), C. O’Connor (Duke University
Medical Center), C. Sueta (University Of North Carolina
At Chapel Hill).
Ohio
P. Amsterdam (Cardiovascular Research Institute, Inc.),
E. Chung (Lindner Clinical Trial Center), D. Grech (North
Ohio Research Ltd.), M. Traboulssi (North Ohio Research,
Ltd.), D. Utlak (United Health Network, Ltd.).
Oregon
S. Lewis (Northwest Cardiovascular Institute).
Pennsylvania
R. Rodriquez (Chestnut Hill Cardiology Ltd.), R. Small
(Lancaster Heart Foundation).
South Carolina
T. O’Brien (Medical University Of South Carolina), M.
Zile (Medical University Of South Carolina).
Tennessee
F. McGrew (Stern Cardiovascular Center, PA).
Texas
S. Blois (Austin Heart, PA Research Account).
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Virginia
R. Goulah (DUCCS Of South Boston), T. Nygaard (Car-
diovascular Associates Of Central VA, Inc.), M. Peberdy
(Virginia Commonwealth University).
Washington
D. Stagaman (Rockwood Clinic Cardiology @ Heart
Institute).
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